UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

Leukemia, 2014-01, Vol.28 (1), p.78-87

2014

Link zum Volltext

Verfügbarkeit prüfen

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE

HemaSphere, 2023-04, Vol.7 (Suppl), p.16-16

2023

Link zum Volltext

Verfügbarkeit prüfen

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

Leukemia, 2013-06, Vol.27 (6), p.1301-1309

2013

Link zum Volltext

Verfügbarkeit prüfen

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

Leukemia, 2012-02, Vol.26 (2), p.244-254

2012

Link zum Volltext

Verfügbarkeit prüfen

The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis)

Haematologica (Roma), 2016-06, Vol.101 (6), p.688

2016

Link zum Volltext

Verfügbarkeit prüfen

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron

Leukemia, 2015-01, Vol.29 (1), p.188-195

2015

Link zum Volltext

Verfügbarkeit prüfen

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

Leukemia, 2010-10, Vol.24 (10), p.1799-1804

2010

Link zum Volltext

Verfügbarkeit prüfen

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

Blood, 2003-10, Vol.102 (8), p.3025-3027

2003

Link zum Volltext

Verfügbarkeit prüfen

p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

Leukemia, 2011-11, Vol.25 (11), p.1739-1750

2011

Link zum Volltext

Verfügbarkeit prüfen

CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors

Leukemia, 2012-07, Vol.26 (7), p.1547-1554

2012

Link zum Volltext

Verfügbarkeit prüfen

Fludarabine i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

Bone marrow transplantation (Basingstoke), 2008-06, Vol.41 (11), p.935-940

2008

Link zum Volltext

Verfügbarkeit prüfen

Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation

Oncogenesis (New York, NY), 2013-11, Vol.2 (11), p.e78-e78

2013

Link zum Volltext

Verfügbarkeit prüfen

310 RISK OF BONE MARROW FAILURE CONDITIONS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES

Leukemia research, 2015-04, Vol.39, p.S154-S154

2015

Link zum Volltext

Verfügbarkeit prüfen

P-010 Distinct methylation signature in MDS patients with SF3B1 mutations confers a novel mechanism of disease pathogenesis

Leukemia research, 2013-05, Vol.37, p.S27-S27

2013

Link zum Volltext

Verfügbarkeit prüfen

Coincident myelodysplastic syndrome and T‐cell large granular lymphocytic disease: clinical and pathophysiological features

British journal of haematology, 2001-01, Vol.112 (1), p.195-200

2001

Link zum Volltext

Verfügbarkeit prüfen

Differences in Iron Distribution in Patients with Myelodysplastic Syndromes Carrying SF3B1 Mutations Using Energy-dispersive X-ray Spectroscopy (XEDS) and Electron-Energy Loss Spectroscopy (EELS)

Microscopy and microanalysis, 2013-08, Vol.19 (S2), p.234-235

2013

Link zum Volltext

Verfügbarkeit prüfen

Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma

Bone marrow transplantation (Basingstoke), 2006-06, Vol.37 (12), p.1099-1102

2006

Link zum Volltext

Verfügbarkeit prüfen

Comparable kinetics of myeloablation between fludarabine full-dose busulfan and fludarabine melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation

Bone marrow transplantation (Basingstoke), 2006-10, Vol.38 (7), p.477-482

2006

Link zum Volltext

Verfügbarkeit prüfen

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE

HemaSphere, 2023-04, Vol.7 (S1), p.16-16

2023

Link zum Volltext

Verfügbarkeit prüfen

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

JAMA : the journal of the American Medical Association, 2003-04, Vol.289 (13), p.1645

2003

Link zum Volltext

Verfügbarkeit prüfen

The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up

American journal of hematology, 2010-06, Vol.85 (6), p.403-408

2010

Link zum Volltext

Verfügbarkeit prüfen

Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A

Blood, 2004-06, Vol.103 (11), p.4102-4110

2004

Link zum Volltext

Verfügbarkeit prüfen

Advances in experimental treatment of β-thalassaemia

Expert opinion on investigational drugs, 2001-05, Vol.10 (5), p.925-934

2001

Link zum Volltext

Verfügbarkeit prüfen

Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

Blood, 2003-12, Vol.102 (12), p.3865-3870

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(55)
Buchkapitel
(2)

Sprache

Englisch
(57)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Life Sciences & Biomedicine
(41)
Humans
(33)
Hematology
(26)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Oncology
(18)
Adult
(16)
Hematologic And Hematopoietic Diseases
(16)
Middle Aged
(15)
Female
(12)
Male
(12)
Aged
(9)
Animals
(9)
Leukemia
(9)
Mutation
(9)
Genetic Aspects
(8)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(8)
Stem Cells
(8)
Myelodysplastic Syndromes
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis)

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors

Dynamics of clonal evolution in myelodysplastic syndromes

Fludarabine i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation

310 RISK OF BONE MARROW FAILURE CONDITIONS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES

P-010 Distinct methylation signature in MDS patients with SF3B1 mutations confers a novel mechanism of disease pathogenesis

Coincident myelodysplastic syndrome and T‐cell large granular lymphocytic disease: clinical and pathophysiological features

Differences in Iron Distribution in Patients with Myelodysplastic Syndromes Carrying SF3B1 Mutations Using Energy-dispersive X-ray Spectroscopy (XEDS) and Electron-Energy Loss Spectroscopy (EELS)

Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma

Comparable kinetics of myeloablation between fludarabine full-dose busulfan and fludarabine melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation

5613127 PHARMACOKINETICS AND PHARMACODYNAMICS OF AN INNOVATIVE ORAL FORMULATION OF DECITABINE AND TETRAHYDROURIDINE IN HEALTHY PEOPLE

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up

Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A

Advances in experimental treatment of β-thalassaemia

Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

Suchergebnisse filtern